Vanguard Group Inc. Has $4.01 Billion Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Vanguard Group Inc. grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,709,510 shares of the company’s stock after buying an additional 6,257 shares during the period. Vanguard Group Inc. owned approximately 11.86% of IDEXX Laboratories worth $4,014,300,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Flossbach Von Storch SE lifted its holdings in IDEXX Laboratories by 5,439.3% in the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock worth $195,696,000 after purchasing an additional 464,791 shares during the last quarter. William Blair Investment Management LLC boosted its holdings in shares of IDEXX Laboratories by 701.6% during the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock worth $174,527,000 after buying an additional 369,471 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of IDEXX Laboratories by 265.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after buying an additional 316,048 shares during the period. Seilern Investment Management Ltd acquired a new position in IDEXX Laboratories in the 4th quarter valued at $113,104,000. Finally, Vontobel Holding Ltd. increased its stake in shares of IDEXX Laboratories by 90.1% in the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock worth $173,051,000 after purchasing an additional 198,404 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on IDXX shares. Morgan Stanley reduced their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Barclays raised their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Finally, Leerink Partners initiated coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Stock Up 0.6 %

Shares of IDXX opened at $423.60 on Tuesday. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a 50-day moving average price of $437.38 and a two-hundred day moving average price of $444.44. The stock has a market cap of $34.34 billion, a price-to-earnings ratio of 39.70, a P/E/G ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $548.88.

Insiders Place Their Bets

In other news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.